We evaluated two putative moderators of treatment outcome as well as the role of Headache Management Self-Efficacy (HMSE) in mediating treatment outcomes in the drug and non-drug treatment of chronic tension-type headache (CTTH). Subjects were 169 participants (M = 38 yrs.; 77% female; M headache days/mo. = 22) who received one of four treatments in the treatment of CTTH trial (JAMA, 2001; 285: 2208-15): tricyclic antidepressant medication, placebo, (cognitive-behavioral) stress-management therapy plus placebo, and stress-management therapy plus antidepressant medication. Severity of CTTH disorder and the presence of a psychiatric (mood or anxiety) disorder were found to moderate outcomes obtained with the three active treatments and with placebo, as well as to moderate the role of HMSE in mediating improvements. Both moderator effects appeared to reflect the differing influence of the moderator variable on each of the three active treatments, as well as the fact that the moderator variables exerted the opposite effect on placebo than on the active treatments. HMSE mediated treatment outcomes in the two stress-management conditions, but the pattern of HMSE mediation was complex, varying with the treatment condition, the outcome measure, and the moderator variable. Irrespective of the severity of the CTTH disorder HMSE fully mediated observed improvements in headache activity in the two stress-management conditions. However, for patients with a mood or anxiety disorder HMSE only partially mediated improvements in headache disability, suggesting an additional therapeutic mechanism is required to explain observed improvements in headache disability in the two stress-management conditions. Ó
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Introduction
Tricyclic antidepressants are the primary drug therapy for chronic tension-type headache, with amitriptyline hydrochloride the first-line treatment [2,5,15,50,61,71,74]. Cognitive-behavioral stress-management therapy is also effective in managing tension-type headache, and when compared to relaxation and biofeedback therapies appear more effective [9,11,27,79]. The treatment of chronic tension-type headache (TCTH) trial reported that, relative to placebo, brief cognitive-behavioral stress-management therapy, tricyclic antidepressant medication, and their combination proved equally effective in improving chronic tension-type headaches and reducing headache-related disability, with improvements occurring most rapidly in the two groups that received antidepressant medication [37] . However, at Month 8 the primary endpoint, the proportion of participants clinically improved (P50% reduction in headache activity) was greater with the combined treatment (64%) than with either antidepressant medication alone (35%) or with stress-management therapy alone (38%).
Clinical trials can provide information about moderator effects, or relationships between patient characteristics and treatment response, in addition to information about overall treatment effects [49] . This information can guide efforts to match patients with the most effective treatment and efforts to develop more effective treatments for unresponsive subpopulations of patients [49] . In the clinical literature, two patient characteristics that may influence outcomes in the treatment of chronic tension-type headache have been identified: (1) severity of chronic tension-type headache disorder, loosely defined by a greater number of days with headaches, as well as by greater headache severity or impairment in function, and (2) the presence of a co-morbid mood or anxiety disorder [3, 7, 12, 25, 28, 32, 34, 51, 55, 62, 65] . To our knowledge, neither variable has been formally examined as a moderator for the tricyclic antidepressant medication and cognitive-behavioral stress-management therapies that appear to be the primary drug and psychological treatments for chronic tension-type headache.
Clinical trials also can provide information about mediator effects, or therapeutic mechanisms that lead to improvement. This
